The Biosimilar Red Tape Elimination Act streamlines the approval process for biosimilar drugs—lower-cost alternatives to expensive biologic medications—by removing the separate "interchangeability" designation step that currently requires additional testing. Under this bill, biosimilar drugs would automatically be considered interchangeable with their brand-name counterparts upon FDA approval, except in cases where another biosimilar is already under an exclusivity period for the same reference drug. The changes take effect 60 days after the bill's enactment, and the FDA has 18 months to update its guidance documents to reflect the new rules. While the bill eliminates paperwork requirements for manufacturers, it does not change the underlying scientific standards the FDA uses to determine whether a biosimilar is safe and effective, meaning patients should receive the same level of safety oversight while companies face fewer bureaucratic hurdles.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.